AMGN

SEC source: 0000318154-26-000137 · form4.xml · derivative · entry 4

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,252 shares

Expires 2027-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000137 · form4.xml · nonDerivative · entry 3

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,404

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

F2 · balance_after: These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000137 · form4.xml · nonDerivative · entry 2

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,656

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000137 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,404

SEC source: 0000318154-26-000131 · form4.xml · nonDerivative · entry 1

Drake Michael V · CIK 0001938942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,876.1633

F1 · balance_after: These shares include 377 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000132 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,990.452

F1 · balance_after: These shares include 1,652 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000133 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,485.9046

F1 · balance_after: These shares include 460 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000135 · form4.xml · nonDerivative · entry 1

Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,080

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 8/7/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000129 · form4.xml · derivative · entry 7

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,948

Underlying: Common Stock · 1,000 shares

Expires 2029-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000129 · form4.xml · derivative · entry 6

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,970 shares

Expires 2028-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000129 · form4.xml · nonDerivative · entry 4

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,340

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

F2 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000129 · form4.xml · nonDerivative · entry 3

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000129 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,340

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

SEC source: 0000318154-26-000129 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,310

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000130 · form4.xml · derivative · entry 6

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,821 shares

Expires 2028-04-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000130 · form4.xml · derivative · entry 5

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,069 shares

Expires 2027-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000130 · form4.xml · nonDerivative · entry 4

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,462

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

F2 · price: The price reported is an average price of $402.5444 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F3 · balance_after: These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000130 · form4.xml · nonDerivative · entry 3

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,283

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000130 · form4.xml · nonDerivative · entry 2

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,462

F1 · shares: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

F2 · price: The price reported is an average price of $402.5444 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

SEC source: 0000318154-26-000130 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,531

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000318154-26-000098 · form4.xml · nonDerivative · entry 1

Austin Wanda M · CIK 0001690882 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,018

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

SEC source: 0000318154-26-000099 · form4.xml · nonDerivative · entry 1

Drake Michael V · CIK 0001938942 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,774.2869

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 339 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000100 · form4.xml · nonDerivative · entry 1

Druker Brian · CIK 0001740205 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,391

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000101 · form4.xml · nonDerivative · entry 1

ECKERT ROBERT · CIK 0001194256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,251

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 3,943 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000102 · form4.xml · nonDerivative · entry 1

Garland Greg C. · CIK 0001503107 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,848

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

SEC source: 0000318154-26-000103 · form4.xml · nonDerivative · entry 1

HOLLEY CHARLES M · CIK 0001216478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,799.0331

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 1,564 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000104 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,358.7361

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 418 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000105 · form4.xml · nonDerivative · entry 1

Jacks Tyler · CIK 0001464237 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,284

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 2,975 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000106 · form4.xml · nonDerivative · entry 1

Klotman Mary E. · CIK 0002020575 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,211

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 18 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000107 · form4.xml · nonDerivative · entry 1

Kullman Ellen Jamison · CIK 0001303141 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,535.9807

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 2,121 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000108 · form4.xml · nonDerivative · entry 1

MILES AMY E · CIK 0001248617 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,640

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.

F2 · balance_after: These shares include 408 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000083 · form4.xml · nonDerivative · entry 1

Bradner James E. · CIK 0002005159 · EVP, Research and Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,016

F1 · balance_after: These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000084 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 505,160

F1 · balance_after: These shares include 1,273 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000085 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,222

F1 · balance_after: These shares include 386 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000086 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,712

F1 · price: These shares include 311 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000087 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,150

F1 · balance_after: These shares include 359 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000088 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,330

F1 · balance_after: These shares include 58 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000089 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,394

F1 · balance_after: These shares include 59 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000090 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,444

F1 · balance_after: These shares include 99 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000091 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,256

F1 · balance_after: These shares include 350 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000092 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,847

F1 · balance_after: These shares include 327 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000093 · form4.xml · nonDerivative · entry 1

Busch Matthew C. · CIK 0001987926 · VP, Finance & CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,344

F1 · balance_after: These shares include 39 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000072 · form4.xml · nonDerivative · entry 2

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,369

F2 · balance_after: These shares include 388 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000073 · form4.xml · nonDerivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP & Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,812

F2 · balance_after: These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000074 · form4.xml · nonDerivative · entry 2

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,595

F2 · balance_after: These shares include 116 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000075 · form4.xml · nonDerivative · entry 2

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,487

F2 · balance_after: These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000076 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,418

F2 · balance_after: These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000077 · form4.xml · nonDerivative · entry 2

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,706

F2 · balance_after: These shares include 424 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000078 · form4.xml · nonDerivative · entry 2

Graham Jonathan P · CIK 0001365306 · EVP & Gen. Counsel & Sec.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,211

F2 · balance_after: These shares include 370 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000079 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,837

F2 · balance_after: These shares include 458 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.